What is BBNX's current stock price?

BBNX (Beta Bionics, Inc.) is currently trading at $11.82 with a market cap of $526.7M.

What sector is Beta Bionics, Inc. in?

Beta Bionics, Inc. (BBNX) operates in the Healthcare sector, specifically in the Medical - Equipment & Services industry.

Is BBNX a good stock to buy?

Analysts have a Buy consensus on BBNX with a price target of $21.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

BBNX Beta Bionics, Inc.

Healthcare

$11.82+11.40%ClosedMarket Cap: $526.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.94

P/S

4.78

EV/EBITDA

-7.25

DCF Value

$-156.71

FCF Yield

-11.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

57.2%

Operating Margin

-70.1%

Net Margin

-60.3%

ROE

-23.0%

ROA

-21.8%

ROIC

-27.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$27.6M	$-21.9M	$—
Q4 null	$32.1M	$-13.5M	$—
FY null	$100.3M	$-73.2M	$—
Q3 null	$27.3M	$-14.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$21.00

Target (Median)

$22.00

Target Range

$14.00 - $25.00

1 Strong Buy7 Buy3 Hold0 Sell0 Strong Sell

B of A SecuritiesNeutral

2026-05-18

Leerink PartnersOutperform

2026-04-22

StifelBuy

2026-04-22

Truist SecuritiesBuy

2026-04-15

Goldman SachsBuy

2026-04-09

Trading Activity

Insider Trades

View All

Russell Steven Jonofficer: Chief Medical Officer

SellMon Mar 16

Hopman Markofficer: Chief Commercial Officer

SellMon Mar 16

Hopman Markofficer: Chief Commercial Officer

SellMon Mar 16

Saint Seandirector, officer: President & CEO

SellFri Mar 13

Russell Steven Jonofficer: Chief Medical Officer

SellFri Mar 13

Company Info

Sector

Healthcare

Industry

Medical - Equipment & Services

Country

Exchange

—

Beta

3.28

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.

Peers